ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag cancer policy nih

Controversy Mounts Over Gene Patenting Policy
Scott Veggeberg | Apr 26, 1992 | 5 min read
Scientists in industry and academia foresee trouble as NIH persists in claiming ownership over partial sequences Date: April 27, 1992 The reviews from the scientific community remain mostly negative over the National Institutes of Health's patent application for a total of 2,722 partial human gene sequences. Academic researchers, who say they are mostly unaffected by the patenting process, nevertheless are appalled; and while some in the commercial sector of the biotech community now believe
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard
What Budget Cuts Might Mean for US Science
Diana Kwon | Mar 21, 2017 | 5 min read
A look at the historical effects of downsized research funding suggests that the Trump administration’s proposed budget could hit early-career scientists the hardest.  
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
Of Cells and Limits
Anna Azvolinsky | Mar 1, 2015 | 9 min read
Leonard Hayflick has been unafraid to speak his mind, whether it is to upend a well-entrenched dogma or to challenge the federal government. At 86, he’s nowhere near retirement.
Snub for NYC biotech hub
Barbara Nasto(barbaranasto@yahoo.com) | Oct 8, 2002 | 2 min read
Plan for downtown bioscience center popular with all but state legislators.
Immune to Failure
Karen Hopkin | Feb 1, 2013 | 9 min read
With dogged persistence and an unwillingness to entertain defeat, Bruce Beutler discovered a receptor that powers the innate immune response to infections—and earned his share of a Nobel Prize.
Observers Praise AIDS Report But Foresee Problems In Implementation
Steven Benowitz | May 12, 1996 | 10 min read
Problems In Implementation LOUD AND CLEAR: Attorney Lynda Dee stresses the need for communication among the institutes. When a federally appointed panel announced in March the results of its 15-month-long review of the United States government's AIDS research program, AIDS activists as well as scientists cheered. The National Institutes of Health's AIDS Research Program Evaluation Working Group's recommendations largely called for scrapping what the group saw as outdated and ineffective polic
Recent Rash Of Misconduct Cases Puts Self-Monitoring Under Scrutiny
Jeffrey Mervis | Sep 3, 1989 | 6 min read
WASHINGTON—Last month, the Public Health Service issued regulations on how federal grantees should respond to allegations of scientific misconduct. The new rules, which take effect November 8, require universities and other institutions to certify that they will follow specific procedures and meet certain timetables in investigating and reporting allegations of misconduct involving their employees. By putting the burden on the institution, the government is abiding by the wishes of t

Run a Search

ADVERTISEMENT